Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

2019 Multidisciniplary NET Disease Symposium

North American Neuroendocrine Tumor Society (NANETS)

ESMO 2019 Annual Congress

European Society for Medical Oncology (ESMO)

2019 SNMMI Annual Meeting

Society of Nuclear Medicine and Medical Imaging (SNMMI)

2019 ASCO Annual Meeting

American Society of Clinical Oncology (ASCO)

Congrès National GTE (Groupe d’études des Tumeurs Neuroendocrines) 2018

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

AAA today announced that it has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. LUTATHERA®, which received orphan drug designation from the FDA, is a first-in-class drug and the first available FDA-approved Peptide Receptor Radioisotope Therapy (PRRT), a form of targeted treatment comprising a targeting molecule that carries a radioactive component.

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA®) and Accelerate Development of Theragnostic Pipeline.

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

JFHOD 2018